Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02032407 · ClinicalTrials.gov registry record · Phase 4
A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris
A Phase 4 study of Acne Vulgaris, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT02032407 is a Phase 4 study of Acne Vulgaris that has completed, run by Allergan. The registered enrollment target is 68 participants, below the 274-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02032407, a Phase 4 study of Acne Vulgaris, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effect of dapsone gel in female subjects with skin of color (Fitzpatrick Skin Types IV, V, and VI) with acne vulgaris.
Conditions Studied
Interventions
- DRUG Dapsone Gel
Study Locations (1)
District of Columbia
- - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02032407
The ClinicalTrials.gov registry entry for NCT02032407 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 274-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (75% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Dapsone Gel is the first listed.
NCT02032407 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02032407 about?
NCT02032407 is a clinical study titled "A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris". This study will evaluate the effect of dapsone gel in female subjects with skin of color (Fitzpatrick Skin Types IV, V, and VI) with acne vulgaris.
What is the current status of trial NCT02032407?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 68 participants. The study started on 2013-12. Estimated completion is 2014-09.
What conditions does trial NCT02032407 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT02032407?
The interventions under investigation include: Dapsone Gel (DRUG).
Who is sponsoring clinical trial NCT02032407?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02032407 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
ACTIVE NOT RECRUITING · Phase 4
-
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 4
-
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
COMPLETED · Phase 4
-
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
COMPLETED · Phase 4
-
Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
COMPLETED · Phase 4
-
Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.